Stratos Wealth Partners, Ltd. Galectin Therapeutics Inc Transaction History
Stratos Wealth Partners, Ltd.
- $6.79 Billion
- Q3 2024
A detailed history of Stratos Wealth Partners, Ltd. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Stratos Wealth Partners, Ltd. holds 40,450 shares of GALT stock, worth $116,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,450
Previous 40,450
-0.0%
Holding current value
$116,496
Previous $91,000
21.98%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$6.15 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$4.5 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$3.4 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$2.48 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.39 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $171M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...